Cellectis, a pioneering global clinical-stage biopharmaceutical company headquartered in Paris, has successfully raised $41 million in its latest funding round, a significant boost for its mission to develop innovative treatments for patients facing unmet medical needs. With over 25 years of expertise in gene editing, Cellectis is a recognized leader utilizing its proprietary TALEN庐 technology to create allogeneic CAR-T cells that effectively target and combat various forms of cancer. This investment will accelerate the advancement of their clinical programs that are currently focusing on B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL), and acute myeloid leukemia (AML).
Cellectis's commitment to end-to-end gene editing and manufacturing allows it to maintain complete control over its CAR-T therapy processes, with starting materials sourced from France and products developed in North Carolina. The recent funding will not only enhance their clinical programs but also bolster ongoing collaborations, such as the partnership with AstraZeneca, aimed at discovering new product candidates in oncology, immunology, and rare disease treatments. As a Nasdaq-listed company (ticker: CLLS) and a key competitor in the allogeneic CAR-T cell landscape, Cellectis is poised for transformative growth. This financial backing will help propel their research efforts, ultimately working towards the vital goal of delivering effective and life-saving treatments to patients. For more details on Cellectis and its groundbreaking work, feel free to visit their website at www.cellectis.com or follow their journey on social media.
